GUILFORD, Conn.--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY), a digital health company transforming care with handheld, whole-body ultrasound, today introduced Butterfly Blueprint™, a system-wide platform designed to support the scaled deployment of ultrasound across hospitals and health systems to empower more-informed clinical decisions from the bedside and encounter-based workflow.
Leveraging Butterfly’s unique combination of a whole-body handheld ultrasound device, software, and services, Blueprint brings hospitals and health systems a complete ultrasound solution. This system-wide offering promotes improved patient care via accessible imaging across multiple disciplines and care settings. By integrating into health systems’ clinical and administrative systems and workflows, Blueprint delivers a clinical assessment tool at scale.
“Ultrasound provides valuable information. The ability to enable the practical application of ultrasound into the clinical workflow to inform clinical decision making is powerful,” said Dr. Todd Fruchterman, Butterfly Network's President and Chief Executive Officer. “Butterfly Blueprint empowers an evolved point-of-care toolkit for hospitals and health systems – one that transcends beyond touch, listening, and surface visuals, and beyond habit-based imaging and lab orders. With Butterfly, clinicians across all disciplines now have a strategic tool that we believe allows them to see and know sooner, helping them drive better care decisions, efficiency, and outcomes.”
Butterfly Blueprint is complemented with a rich set of optional software and services including Caption Health’s AI-guided software. Caption AI™ empowers healthcare professionals without sonography expertise to capture and interpret cardiac ultrasound images for earlier disease detection and better patient management. The Centers for Medicare and Medicaid Services (CMS) has approved new technology add-on payments (NTAP) for Caption Guidance™– a designation awarded to new medical technologies and services that are expected to substantially improve the diagnosis or treatment of Medicare beneficiaries.
“Deployment on the Blueprint platform is helping us fulfill our mission to put enhanced diagnostic capabilities in more hands and increase access for patients,” said Steve Cashman, President and CEO of Caption Health. “By integrating Caption AI with Butterfly iQ+, we’re expanding diagnostic toolkits for hospitals, health systems, and wherever a patient needs care. The insights provided by a high-quality ultrasound exam are critical for better care and earlier disease detection. Butterfly and Caption are making that vision not just a possibility, but a reality.”
The University of Rochester Medical Center (URMC), upstate New York’s largest and most comprehensive healthcare system, announced earlier this year that it will deploy Butterfly Blueprint, bringing it first to medical students, primary care providers, and home care nurses. As quoted within the announcement, Dr. David L. Waldman, Chief Medical IT Development Officer and former Chair of Imaging Sciences at URMC said, “The deployment of innovative ultrasound technology has the potential to redefine the point-of-care clinical standard and serve as an enhancement to the use of the stethoscope. Enterprise deployment of point of care ultrasound will ultimately enable every clinician, across all departments, to quickly image patients where they are located.”
With Butterfly Blueprint, hospitals and health systems like URMC can rapidly and easily access ultrasound-enabled insights at the point of care through capabilities such as intuitive, mobile-first workflows; 20+ ready-to-use presets for procedural guidance; and device-agnostic software that integrates with non-Butterfly devices, as well as with other clinical and administrative systems including the PACS and EMR. Butterfly probes connect with compatible Apple and Android smartphones and tablets for display and support streamlined information sharing. Blueprint is also supported with Butterfly Academy, an extensive set of ultrasound specific courses and curricula.
To learn more about Butterfly Blueprint™ visit https://www.butterflynetwork.com/blueprint. If in attendance, please visit Butterfly at booth #2135 at HIMSS Global Health Conference & Exhibition, March 14-18, 2022. To learn more about Caption AI, HIMSS attendees can visit Kiosk 5676-09 in the Value of Healthcare Pavilion or visit captionhealth.com.
About Butterfly Network
Founded by Dr. Jonathan Rothberg in 2011, and recently listed on the New York Stock Exchange through a business combination with Longview Acquisition Corp., Butterfly created the world's first handheld, single probe whole-body ultrasound system using semiconductor technology, the Butterfly iQ+. Butterfly's mission is to democratize medical imaging and contribute to the aspiration of global health equity, making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Through its proprietary Ultrasound-on-Chip™ technology, Butterfly is paving the way for earlier detection and remote management of health conditions around the world. The Butterfly iQ+ can be purchased online today by healthcare practitioners in the United States, Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, New Zealand, Norway, Poland, Portugal, Spain, Sweden, Switzerland, and the United Kingdom.
Butterfly Blueprint™ is Butterfly Network’s revamped offering for enterprises. It supports healthcare systems by giving them access to new, diagnostically-meaningful clinical information at the bedside while helping to support procedure availability and expediency across care settings. By pairing the world’s first handheld, easy-to-use, whole-body ultrasound probe with intuitive, mobile-first workflow unlocks powerful new uses for ultrasound across the care continuum—it does for imaging what the stethoscope did for auscultation. This solution is enabled through a dedicated customer experience team and proven processes that include solution advisory, implementation services, and post-go-live support.
The Butterfly iQ+ probe is a prescription device intended for trained healthcare professionals only.
Butterfly Network, Inc. Forward Looking Statements This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Butterfly's actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," 'plan,' "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward- looking statements. These forward-looking statements include, without limitation, Butterfly's goals and expectations with respect to its strategic partnership with University of Rochester Medical Center, and Butterfly's development and commercialization efforts and business plans under the caption "About Butterfly Network." These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside of Butterfly's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on Butterfly's business; the ability to recognize the anticipated benefits of its business combination with Longview Acquisition Corp.; Butterfly's ability to grow and manage growth profitably; the success, cost and timing of Butterfly's product and service development activities; the potential attributes and benefits of Butterfly's products and services; Butterfly's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; Butterfly's ability to identify, in-license or acquire additional technology; Butterfly's ability to maintain its existing license, manufacture, supply and distribution agreements; Butterfly's ability to compete with other companies currently marketing or engaged in the development of products and services that Butterfly is currently marketing or developing; changes in applicable laws or regulations; the size and growth potential of the markets for Butterfly's products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of Butterfly's products and services and reimbursement for medical procedures conducted using its products and services; Butterfly's estimates regarding expenses, revenue, capital requirements and needs for additional financing; Butterfly's financial performance; Butterfly's ability to raise financing in the future; and other risks and uncertainties indicated from time to time in Butterfly's filings with the Securities and Exchange Commission. Butterfly cautions that the foregoing list of factors is not exclusive. Butterfly cautions you not to place undue reliance upon any forward-looking statements, which speak only as of the date of this press release. Butterfly does not undertake or accept any obligation or undertake to release publicly any updates or revisions to any forward-looking statements to reflect any change in Butterfly's expectations or any change in events, conditions or circumstances on which any such statement is based.
